 Michael Knitz
Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 9 | 2023 | 427 | 2.150 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2022 | 339 | 0.840 |
Why?
| | Immunotherapy | 4 | 2023 | 474 | 0.790 |
Why?
| | Radiation Tolerance | 1 | 2021 | 92 | 0.700 |
Why?
| | Carcinoma, Pancreatic Ductal | 4 | 2023 | 211 | 0.670 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 152 | 0.640 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 261 | 0.600 |
Why?
| | Dendritic Cells | 1 | 2021 | 435 | 0.590 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 636 | 0.550 |
Why?
| | Pancreatic Neoplasms | 4 | 2023 | 731 | 0.500 |
Why?
| | Tumor Microenvironment | 5 | 2022 | 430 | 0.430 |
Why?
| | Ephrin-B2 | 3 | 2022 | 36 | 0.420 |
Why?
| | Receptor, EphB4 | 2 | 2022 | 23 | 0.380 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 66 | 0.290 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 2710 | 0.260 |
Why?
| | Adenocarcinoma | 2 | 2023 | 795 | 0.260 |
Why?
| | Mice | 10 | 2023 | 14871 | 0.250 |
Why?
| | Interleukin-2 | 2 | 2023 | 413 | 0.250 |
Why?
| | Spiral Cone-Beam Computed Tomography | 1 | 2023 | 3 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 173 | 0.220 |
Why?
| | Tumor Burden | 2 | 2021 | 259 | 0.220 |
Why?
| | Vasculitis | 1 | 2023 | 66 | 0.200 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 37 | 0.200 |
Why?
| | Radioimmunotherapy | 1 | 2021 | 11 | 0.190 |
Why?
| | Combined Modality Therapy | 2 | 2022 | 1121 | 0.190 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1144 | 0.190 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 64 | 0.190 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 18 | 0.190 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 39 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.180 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2021 | 28 | 0.180 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 116 | 0.180 |
Why?
| | Mice, Knockout | 3 | 2021 | 2570 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 48 | 0.180 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 41 | 0.180 |
Why?
| | Receptors, Complement | 1 | 2021 | 111 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 72 | 0.180 |
Why?
| | Animals | 10 | 2023 | 31708 | 0.170 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 111 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 128 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 167 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2021 | 2187 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 453 | 0.160 |
Why?
| | Membrane Proteins | 2 | 2021 | 1019 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2021 | 366 | 0.150 |
Why?
| | Glioblastoma | 1 | 2020 | 253 | 0.150 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 4694 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1141 | 0.120 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1040 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1737 | 0.110 |
Why?
| | Phenotype | 1 | 2021 | 2796 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 849 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 698 | 0.080 |
Why?
| | Humans | 10 | 2023 | 114698 | 0.070 |
Why?
| | Survival Rate | 2 | 2021 | 1644 | 0.070 |
Why?
| | Cell Movement | 2 | 2021 | 869 | 0.070 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2023 | 25 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2023 | 14 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 154 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3329 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2022 | 139 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2363 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 194 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 304 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 170 | 0.040 |
Why?
| | Complement C3 | 1 | 2021 | 188 | 0.040 |
Why?
| | Software | 1 | 2023 | 530 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 317 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 442 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 630 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 380 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 687 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2765 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1569 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 720 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2380 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1355 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2480 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 6116 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 9088 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4515 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 12555 | 0.020 |
Why?
| | Female | 2 | 2021 | 59520 | 0.010 |
Why?
|
|
Knitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|